All In Biotech

Drug Trial Radar · NCT02495922

A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

Last checked: Nov 20, 2026Latest source record: Sep 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 564 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

564

Actual

Start

Jun 2015

Primary completion

Jun 24, 2021

Study completion Jun 24, 2021

Sponsor

Lead sponsor
University of Heidelberg Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 13, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment

Conditions

  • Multiple Myeloma

Interventions

  • elotuzumabDrug

    10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)

  • LenalidomideDrug

    25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)

  • BortezomibDrug

    all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m\^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation

  • DexamethasoneDrug

    20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2). 8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2). 20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2). 12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the best of four treatment strategies regarding Progression Free Survival (PFS)Time frame: time from randomization to progression or death from any cause whichever comes first, censored after two years of maintenance therapy (i.e. approx. after 36 months after randomisation)

Locations

68 sites in 1 country. Site status is shown where the registry gives one.

  • Studienzentrum Aschaffenburg

    Aschaffenburg, Germany

  • MVZ Onkologie gGmbH der Klinikum Mittelbaden gGmbH

    Baden-Baden, Germany

  • HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie

    Berlin, Germany

  • Onkologisches MVZ Berlin Tegel

    Berlin, Germany

  • Charité Campus Benjamin Franklin, III. Med. Abt. (Hämatologie/Onkologie)

    Berlin, Germany

  • Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin

    Bielefeld, Germany

  • Studiengesellschaft Onkologie Bielefeld GbR

    Bielefeld, Germany

  • Hämatologisch-onkologische Schwerpunktpraxis

    Bochum, Germany

  • Medizinische Universitätsklinik, Knappschaftskrankenhaus

    Bochum, Germany

  • Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie

    Bonn, Germany

  • ZAHO, Zentrum für ambulante Hämatologie und Onkologie

    Bonn, Germany

  • Schwerpunktpraxis für Onkologie/Hämatologie

    Bottrop, Germany

  • Klinikum Chemnitz GmbH, Innere Medizin III

    Chemnitz, Germany

  • Universitätsklinikum Köln, Klinik I - Innere Medizin

    Cologne, Germany

  • Onkologisches Studienzentrum Darmstadt

    Darmstadt, Germany

  • Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie

    Darmstadt, Germany

  • HELIOS St. Johannes Klinik, Akademisches Krankenhaus der Heinrich-Heine-Universität Düsseldorf

    Duisburg, Germany

  • MVZ Düsseldorf GmbH

    Düsseldorf, Germany

  • Sana Kliniken Düsseldorf GmbH

    Düsseldorf, Germany

  • Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie

    Düsseldorf, Germany

  • Universitätsklinik Erlangen

    Erlangen, Germany

  • St.-Antonius-Hospital Klinik f. Hämatologie und Onkologie

    Eschweiler, Germany

  • Universitätsklinikum Essen, Klinik für Hämatologie

    Essen, Germany

  • Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation

    Essen, Germany

  • Centrum für Hämatologie und Onkologie Bethanien

    Frankfurt am Main, Germany

  • Agaplesion Markus Krankenhaus

    Frankfurt am Main, Germany

  • Universitätsklinikum Frankfurt, Goethe-Universität Medizinische Klinik II

    Frankfurt am Main, Germany

  • Praxis und Tagesklinik Friedrichshafen

    Friedrichshafen, Germany

  • Gemeinschaftspraxis Schmitt/Eulenbuch

    Gerlingen, Germany

  • Justus-Liebig-Universität, Medizinische Klinik IV

    Giessen, Germany

  • Kath. Krankenhaus Hagen gGmbH, Abt. Hämatologie/Onkologie

    Hagen, Germany

  • Universitätsklinikum Hamburg-Eppendorf, II - Med. Klinik und Poliklinik

    Hamburg, Germany

  • Asklepios Klinik Hamburg Altona, II. Med. Klinik

    Hamburg, Germany

  • Evangelisches Krankhaus Hamm gGmbH

    Hamm, Germany

  • Onkologische Schwerpunktpraxis

    Heidelberg, Germany

  • University Hospital Heidelberg, Med. Klinik V

    Heidelberg, Germany

  • Onkologische Schwerpunktpraxis

    Heilbronn, Germany

  • SLK Kliniken Heilbronn, Med. Klinik III

    Heilbronn, Germany

  • Universitätsklinikum des Saarlandes, Innere Medizin I

    Homburg, Germany

  • Westpfalz-Klinikum GmbH

    Kaiserslautern, Germany

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.